Just caught a snippet of this...
discussed competitive advantage with Concierge (with more and more real world data collection) generating evidence to support the products
On track to deliver fit for purpose products under Schedule 3 when legislation allows
AGH plans to take advantage of the regulation changes? Have invested significant R+D into S3 products already in preparation for the interim decision. CBD 100 would stay in the prescription cannabis space. Moving as quickly as possible.
Canada - HealthCanada (TGA equivalent) are investigating a natural health product pathway for CBD medicines (similar to Aus S3). Good for AGH as already preparing similar products for Aus.
Just caught a snippet of this...discussed competitive advantage...
Add AGH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.75M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.9¢ | $1.913K | 65.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 469462 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 44550 | 3 |
View Market Depth
| Last trade - 10.23am 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.8¢ |
Change
0.000 ( 3.45 %) |
||||
| Open | High | Low | Volume | ||
| 2.9¢ | 2.9¢ | 2.8¢ | 10000 | ||
| Last updated 13.06pm 02/05/2024 ? | |||||
| AGH (ASX) Chart |